Skip to main content

Esophageal & Lung Institute of the Allegheny Health Network Launches Study of Immunotherapy Drug For Advanced Esophageal Cancer

Cancer specialists at the Allegheny Health Network (AHN) Esophageal and Lung Institute are recruiting patients for the first Phase III clinical trial to evaluate an immunotherapy drug, called nivolumab (Opdivo), as a potential treatment option for advanced esophageal cancer. Bristol-Myers Squibb developed nivolumab (Opdivo) and is the Sponsor of this study.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino